Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 163

Similar articles for PubMed (Select 21292300)

1.

The immunohistochemical staining pattern of Gab2 correlates with distinct stages of chronic myeloid leukemia.

Aumann K, Lassmann S, Schöpflin A, May AM, Wöhrle FU, Zeiser R, Waller CF, Hauschke D, Werner M, Brummer T.

Hum Pathol. 2011 May;42(5):719-26. doi: 10.1016/j.humpath.2010.09.012. Epub 2011 Feb 2.

PMID:
21292300
2.

Correlation of marrow iron patterns with disease status of chronic myelogenous leukemia.

Welborn JL, Lewis JP.

Leuk Lymphoma. 1993 Aug;10(6):469-75.

PMID:
8401182
3.

Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression.

Gaiger A, Henn T, Hörth E, Geissler K, Mitterbauer G, Maier-Dobersberger T, Greinix H, Mannhalter C, Haas OA, Lechner K, Lion T.

Blood. 1995 Sep 15;86(6):2371-8.

4.

Fas ligand is highly expressed in acute leukemia and during the transformation of chronic myeloid leukemia to blast crisis.

Lickliter JD, Kratzke RA, Nguyen PL, Niehans GA, Miller JS.

Exp Hematol. 1999 Oct;27(10):1519-27.

PMID:
10517493
5.
6.

Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells.

Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G, Gewirtz AM, Perussia B, Calabretta B.

Blood. 1995 Jul 15;86(2):726-36.

7.

Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.

Gutiérrez-Castellanos S, Cruz M, Rabelo L, Godínez R, Reyes-Maldonado E, Riebeling-Navarro C.

Eur J Haematol. 2004 Apr;72(4):231-8.

PMID:
15089759
8.

Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.

Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, Pattacini L, Goldman JM, Melo JV.

Cancer Res. 2005 Oct 1;65(19):8912-9.

9.

Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression.

Wetzler M, Kurzrock R, Lowe DG, Kantarjian H, Gutterman JU, Talpaz M.

Blood. 1991 Nov 1;78(9):2400-6.

10.

Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells.

Wu CJ, Biernacki M, Kutok JL, Rogers S, Chen L, Yang XF, Soiffer RJ, Ritz J.

Clin Cancer Res. 2005 Jun 15;11(12):4504-11.

11.

BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients.

Verfaillie CM, Bhatia R, Miller W, Mortari F, Roy V, Burger S, McCullough J, Stieglbauer K, Dewald G, Heimfeld S, Miller JS, McGlave PB.

Blood. 1996 Jun 1;87(11):4770-9.

12.

Critical role for Gab2 in transformation by BCR/ABL.

Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K, Gesbert F, Iwasaki H, Li S, Van Etten RA, Gu H, Griffin JD, Neel BG.

Cancer Cell. 2002 Jun;1(5):479-92.

14.
15.

Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.

Koschmieder S, Göttgens B, Zhang P, Iwasaki-Arai J, Akashi K, Kutok JL, Dayaram T, Geary K, Green AR, Tenen DG, Huettner CS.

Blood. 2005 Jan 1;105(1):324-34. Epub 2004 Aug 26.

16.

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M.

N Engl J Med. 2001 Apr 5;344(14):1038-42. Erratum in: N Engl J Med 2001 Jul 19;345(3):232.

17.

[Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].

Liu XL, Zhou SY, Du QF, Zheng WY, Zhang S, Song LL, Xu B, Liu QF, Meng FY.

Ai Zheng. 2004 Apr;23(4):421-5. Chinese.

PMID:
15087031
18.

A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9.

Dash AB, Williams IR, Kutok JL, Tomasson MH, Anastasiadou E, Lindahl K, Li S, Van Etten RA, Borrow J, Housman D, Druker B, Gilliland DG.

Proc Natl Acad Sci U S A. 2002 May 28;99(11):7622-7.

19.

High frequency of RAS oncogene mutation in chronic myeloid leukemia patients with myeloblastoma.

Tanaka K, Takauchi K, Takechi M, Kyo T, Dohy H, Kamada N.

Leuk Lymphoma. 1994 Apr;13(3-4):317-22.

PMID:
8049652
20.

Lineage switch and multilineage involvement in two cases of pH chromosome-positive acute leukemia: evidence for a stem cell disease.

Cuneo A, Balboni M, Piva N, Carli MG, Tomasi P, Previati R, Negrini M, Scapoli G, Spanedda R, Castoldi G.

Haematologica. 1994 Jan-Feb;79(1):76-82.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk